Role of Cytosolic Phospholipase A2 in Retinal Neovascularization

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 2, 2010, Pages 1136-1142

  Barnett, Joshua M ^a   McCollum, Gary W ^a   Penn, John S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CAY 10502; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; MITOGEN ACTIVATED PROTEIN KINASE P38; OXYGEN; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; VASCULOTROPIN; ENZYME INHIBITOR; PTGS2 PROTEIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL HYPOXIA; CELL PROLIFERATION; COMPUTER ANALYSIS; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MUELLER CELL; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; WESTERN BLOTTING; ANIMAL; ANOXIA; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; HUMAN; MALE; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RETINA NERVE CELL; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT, NEWBORN; MALE; OXYGEN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOLIPASES A2, CYTOSOLIC; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RETINAL NEOVASCULARIZATION; RETINAL NEURONS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77449088271     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3691     Document Type: Article

References (60)

1. Klagsbrun M. Regulators of angiogenesis: stimulators, inhibitors, and extracellular matrix. J Cell Biochem. 1991;47(3):199-200.
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931-10934.
3. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87(7):1153-1155.
4. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-674.
5. Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech. 2003;60(1):107-114.
6. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 2001;86(1):23-33.
7. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653-660.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.
9. Steinkuller PG, Du L, Gilbert C, et al. Childhood blindness. J AAPOS. 1999;3(1):26-32.
10. Rahmani B, Tielsch JM, Katz J, et al. The cause-specific prevalence of visual impairment in an urban population: the Baltimore Eye Survey. Ophthalmology. 1996;103(11):1721-1726.
11. Bressler NM, Bressler SB. Preventative ophthalmology: age-related macular degeneration. Ophthalmology. 1995;102(8):1206-1211.
12. 2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-5514.
13. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998;17(11):3005-3015.
14. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat Med. 2005;11(9):992-997.
15. Mizukami Y, Li J, Zhang X, et al. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 2004;64(5):1765-1772.
16. Mizukami Y, Fujiki K, Duerr EM, et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem. 2006;281(20):13957-13963.
17. Jin HG, Yamashita H, Nagano Y, et al. Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression. Neurosci Lett. 2006;408(1):62-67.
18. Aiello LP. Vascular endothelial growth factor: 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci. 1997;38(9):1647-1652.
19. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113(12):1538-1544.
20. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92(23):10457-10461.
21. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92(3):905-909.
22. Robbins SG, Conaway JR, Ford BL, Roberto KA, Penn JS. Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina. Growth Factors. 1997;14(4):229-241.
23. Robbins SG, Rajaratnam VS, Penn JS. Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. Growth Factors. 1998;16(1):1-9.
24. Nandgaonkar BN, Rotschild T, Yu K, Higgins RD. Indomethacin improves oxygen-induced retinopathy in the mouse. Pediatr Res. 1999;46(2):184-188.
25. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108(2):198-204.
26. Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2003;44(3):974-979.
27. Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGFinduced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res. 2004;79(2):275-285.
28. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res. 2005;24(1):87-138.
29. Moolwaney AS, Igwe OJ. Regulation of the cyclooxygenase-2 system by interleukin-1β through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells. Brain Res Mol Brain Res. 2005;137(1-2):202-212.
30. Lin LL, Wartmann M, Lin AY, et al. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993;72(2):269-278.
31. Clark JD, Schievella AR, Nalefski EA, Lin LL. Cytosolic phospholipase A2. J Lipid Mediat Cell Signal. 1995;12(2-3):83-117.
32. Kramer RM, Roberts EF, Hyslop PA, et al. Differential activation of cytosolic phospholipase A2 (cPLA2) by thrombin and thrombin receptor agonist peptide in human platelets: evidence for activation of cPLA2 independent of the mitogen-activated protein kinases ERK1/2. J Biol Chem. 1995;270(24):14816-14823.
33. Rouzer CA, Marnett LJ. Structural and functional differences between cyclooxygenases: fatty acid oxygenases with a critical role in cell signaling. Biochem Biophys Res Commun. 2005;338(1):34-44.
34. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem. 1999;274(33):22903-22906.
35. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387-437.
36. Chang SH, Liu CH, Wu MT, Hla T. Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostaglandins Other Lipid Mediat. 2005;76(1-4):48-58.
37. Hoper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol. 1997;17(6):748-756.
38. Hatazawa R, Tanigami M, Izumi N, et al. Prostaglandin E2 stimulates VEGF expression in primary rat gastric fibroblasts through EP4 receptors. Inflammopharmacology. 2007;15(5):214-217.
39. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci. 1998;39(3):581-591.
40. Ju WK, Kim KY, Neufeld AH. Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia. Exp Eye Res. 2003;77(2):137-145.
41. Penn JS, Song Q, Odonkor C. Nepafenac metabolite, amfenac, inhibits VEGF-induced angiogenesis Presented at: 57th Southeast/ 61st Southwest Regional Meeting; November 1-4, 2005; Memphis, TN. Abstract 529.
42. Lukiw WJ, Ottlecz A, Lambrou G, et al. Coordinate activation of HIF-1 and NF-κB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci. 2003;44(10):4163-4170.
43. Hicks D, Courtois Y. The growth and behaviour of rat retinal Muller cells in vitro, 1: an improved method for isolation and culture. Exp Eye Res. 1990;51(2):119-129.
44. Matsubara TA, Murata TA, Wu GS, Barron EA, Rao NA. Isolation and culture of rat retinal microvessel endothelial cells using magnetic beads coated with antibodies to PECAM-1. Curr Eye Res. 2000;20(1):1-7.
45. Riendeau D, Guay J, Weech PK, et al. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem. 1994;269(22):15619-15624.
46. Lio YC, Reynolds LJ, Balsinde J, Dennis EA. Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim Biophys Acta. 1996;1302(1):55-60.
47. Ludwig J, Bovens S, Brauch C, Elfringhoff AS, Lehr M. Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2α. J Med Chem. 2006;49(8):2611-2620.
48. Lutty GA, McLeod DS. A new technique for visualization of the human retinal vasculature. Arch Ophthalmol. 1992;110(2):267-276.
49. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34(3):576-585.
50. 2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci. 1995;36(10):2063-2070.
51. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001;42(1):283-290.
52. Bullard LE, Qi X, Penn JS. Role for extracellular signal-responsive kinase-1 and-2 in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2003;44(4):1722-1731.
53. Kramer RM, Roberts EF, Um SL, et al. p38 Mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets: evidence that prolinedirected phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem. 1996;271(44):27723-27729.
54. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3(1):53-61.
55. Majima M, Isono M, Ikeda Y, et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn J Pharmacol. 1997;75(2):105-114.
56. Clark JD, Lin LL, Kriz RW, et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 1991;65(6):1043-1051.
57. Kramer RM, Roberts EF, Manetta J, Putnam JE. The Ca2(+)-sensitive cytosolic phospholipase A2 is a 100-kDa protein in human monoblast U937 cells. J Biol Chem. 1991;266(8):5268-5272.
58. Dethlefsen SM, Shepro D, D'Amore PA. Arachidonic acid metabolites in bFGF-, PDGF-, and serum-stimulated vascular cell growth. Exp Cell Res. 1994;212(2):262-273.
59. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002;62(3):625-631.
60. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol. 2002;63(5):817-821.